OraSure Technologies, Inc. (OSUR) SEC Filings & Earnings Calls

HCV Revenue Concentration Risk

“lower HCV revenues due to the expiration and non-renewal of a large customer's HCV testing program.” · word for word

Activist Distraction Risk

“General and administrative expenses increased 14%... largely due to an increase in legal fees and in professional services related to the proxy statement and related stockholder activism costs.”

Cash Burn Risk

“Net cash used in operating activities was $23.8 million for the six months ended June 30, 2026.” · word for word

COVID-19 and Risk Assessment Testing revenues declining to near zero; core business flat YoY.

“COVID-19 revenue $1K vs $28K YoY; Risk Assessment Testing $0 vs $446K.”

Non-GAAP operating loss widening; GAAP profitability driven by non-cash contingent consideration adjustment.

“Non-GAAP operating loss $14.7M vs $13.2M YoY; GAAP operating income includes $22.6M liability reduction.”

Revenue concentration in discontinued product lines

“Risk Assessment Testing revenues are $0 in 2026 as the product line was discontinued and wound down in early 2025.” · word for word

Dependence on international HCV revenue

“This decrease in revenues is largely due to lower international HCV revenues driven by customer ordering patterns and funding constraints.” · word for word

Operating losses and cash burn

“Net cash used in operating activities was $13.9 million.” · word for word

Operating loss widened YoY, indicating cost growth outpacing revenue.

“GAAP operating loss $23.3M vs $17.8M in Q1 2025.”

Revenue decline driven by HCV test and COVID-19 revenue drop.

“Diagnostics revenue down 5% due to lower HCV test revenue; COVID-19 revenue near zero.”

Revenue decline from COVID-19 testing and core business

“Consolidated revenues were $115.0 million in 2025, representing a 38% decrease from 2024.” · word for word

Dependence on U.S. government funding for public health programs

“our customers dealt with elevated uncertainty related to U.S. funding for public health programs and research.” · word for word

Bankruptcy of a large customer in consumer genomics

“a decrease in Sample Management Solution revenue of 25% as a result of government funding challenges and the bankruptcy of a large customer in the consumer genomics segment.” · word for word

Activist standstill limits further stake accumulation

“The Cooperation Agreement also includes customary voting commitments and standstill provisions, subject to certain exceptions, including certain restrictions on the Reporting Persons' ability to acquire additional shares of the Common Stock to the extent such acquisition would cause the Reporting Persons to own more than 9.9% of the then-outstanding shares o” · word for word

Activist standstill limits further stake accumulation

“The Cooperation Agreement also includes customary voting commitments and standstill provisions, subject to certain exceptions, including certain restrictions on the Reporting Persons' ability to acquire additional shares of the Common Stock to the extent such acquisition would cause the Reporting Persons to own more than 9.9% of the then-outstanding shares o” · word for word

Activist pressure; potential board challenge and strategic disruption.

“Altai Capital has made several misleading claims that serve as the basis for its efforts to replace two independent directors.” · word for word

Genomics Market Volatility

“The ancestry portion of the consumer genomics market may be maturing and the Company's sales to customers with offerings in this market have been volatile.” · word for word

Government Funding Risk

“the National Institutes of Health ("NIH") announced on February 7, 2025, a policy significantly reducing research grants by limiting payments for indirect costs.” · word for word

COVID-19 Revenue Decline

“The Company experienced a significant decline in revenues from InteliSwab ® COVID-19 Rapid Test sales in 2024 and 2025, and expects revenues to continue to decline in 2026.” · word for word

Sole-Source Supplier Dependency

“The biological antigens and antibodies, nitrocellulose and certain other components required to make the Company's OraQuick ® HIV, HCV and Ebola products are currently purchased from sole-source suppliers.” · word for word

Minimal risk; resignation is amicable and not due to disagreement.

“Resignation not due to any dispute or disagreement.”

Revenue decline across core segments, especially sample management due to large customer loss

“Core revenues decreased 22% YoY; Sample Management Solutions revenues decreased 39% YoY, with majority of decline attributable to a large customer in the consumer genomics segment.”

Widening operating losses and net losses

“GAAP operating loss was $20.1 million in Q4 2025 compared to $12.4 million in Q4 2024. Net loss was $19.3 million vs $10.8 million.”

Regulatory approval risk; no guarantee of FDA clearance.

“Forward-looking statements highlight uncertainty of regulatory clearances.”

Customer funding uncertainty for public health programs and research continues to pressure revenue.

“Some of our customers continue to experience elevated levels of uncertainty related to funding for public health programs and research.” · word for word

Dependence on HIV test revenue and large consumer genomics customer creates concentration risk.

“Decline attributable to lower revenue from our HIV tests... decline attributable to a large customer in the consumer genomics segment.” · word for word

Customer bankruptcy impact

“Sales of the Company's genomics products are being impacted by a large customer's bankruptcy proceedings.” · word for word

Dependence on government funding

“This decrease in revenues is largely due to lower international HIV revenues driven by reduced funding and customer ordering patterns.” · word for word

Clinical trial cost overrun

“Research and development expenses increased 80% to $10.1 million for the three months ended September 30, 2025 from $5.6 million for the three months ended September 30, 2024 largely due to higher spend incurred for clinical trials.” · word for word